Literature DB >> 24618916

Neonatal/infant validation study of the CAS model 740 noninvasive blood pressure monitor with the Orion/MaxIQ NIBP module.

Sean M Lang1, John S Giuliano, Christopher L Carroll, Ted S Rosenkrantz, Leonard Eisenfeld.   

Abstract

OBJECTIVE: Blood pressure monitoring is an essential vital sign when caring for critically ill children. Invasive monitoring is considered the gold standard, but is not always feasible. The following study compared the CAS model 740 noninvasive blood pressure monitor with the Orion/MaxIQ NIBP module with the reference (invasive arterial measurement). We evaluated the validity of the system using the criteria provided by the Association for the Advancement of Medical Instrumentation.
RESULTS: We performed paired measurements of 29 critically ill neonates and children. For individual paired comparisons, the mean difference in the systolic blood pressure was 2.42 mmHg (SD ± 6.3). The mean difference in the diastolic blood pressure was -1.29 mmHg (SD ± 5.45). The percentage of readings within 5, 10, and 15 mmHg for systolic blood pressure was 65.6, 86.0, and 96.8%, respectively. The percentage of readings within 5, 10, and 15 mmHg for diastolic blood pressure was 77.7, 93, and 95.5%, respectively.
CONCLUSION: The CAS model 740 noninvasive blood pressure monitor with the Orion/MaxIQ NIBP module fulfills the accuracy performance criteria of the Association for the Advancement of Medical Instrumentation. This model may allow for rapid and accurate noninvasive blood pressure monitoring in neonates and children.

Entities:  

Mesh:

Year:  2014        PMID: 24618916     DOI: 10.1097/MBP.0000000000000036

Source DB:  PubMed          Journal:  Blood Press Monit        ISSN: 1359-5237            Impact factor:   1.444


  1 in total

1.  The accuracy of blood pressure measured by arterial line and non-invasive cuff in critically ill children.

Authors:  Rachel Joffe; Jonathan Duff; Gonzalo Garcia Guerra; Jodie Pugh; Ari R Joffe
Journal:  Crit Care       Date:  2016-06-08       Impact factor: 9.097

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.